{
    "nct_id": "NCT06239480",
    "official_title": "SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations",
    "inclusion_criteria": "* Participant must be at least 6 years of age at time of consent\n* Participant must have a clinically confirmed superficial/cutaneous microcystic lymphatic malformation\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 6 Years",
    "exclusion_criteria": "* Participants who have vascular malformations that interfere with evaluating the target microcystic lymphatic malformation\n* Participants with complicated vascular anomalies with severe systemic symptoms that require systemic therapy\n* The participant's treatment area is mainly in any wet mucosa or within the orbital rim\n* Participants who are pregnant or planning to become pregnant",
    "miscellaneous_criteria": "Key"
}